As reported (Zelenay et al., 2015), control and Ptgs1/Ptgs2−/− BRAFV600E tumors were broadly equivalent in terms of total number of CD45+ cells, CD11c+MHCII+ cells, and tumor mass (Figure 1C). This evidence concerns the gene ITGAX and neoplasm.